A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment

Completed
Phase of Trial: Phase II

Latest Information Update: 01 May 2017

At a glance

  • Drugs CERC 301 (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Cerecor
  • Most Recent Events

    • 01 May 2017 Cerecor intends to present additional data from this trial at the American Society of Clinical Psychopharmacologists Annual Meeting, according to a company media release.
    • 03 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 29 Nov 2016 Primary endpoint has not been met. (Change in Bech-6 from baseline), as reported in a Cerecor media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top